These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20106598)

  • 1. Some remarks about the LeishVet directions for the treatment of canine leishmaniasis.
    Lamothe J
    Vet Parasitol; 2010 May; 169(3-4):416-7; author reply 418-20. PubMed ID: 20106598
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of antimonial therapy for canine leishmaniasis on antibody titer.
    Amusategui I; Sainz A; Tesouro MA
    Ann N Y Acad Sci; 1998 Jun; 849():444-6. PubMed ID: 9668509
    [No Abstract]   [Full Text] [Related]  

  • 3. Canine leishmaniasis chemotherapy: dog's clinical condition and risk of Leishmania transmission.
    João A; Pereira MA; Cortes S; Santos-Gomes GM
    J Vet Med A Physiol Pathol Clin Med; 2006 Dec; 53(10):540-5. PubMed ID: 17105576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of two different drug combinations for the treatment of canine leishmaniasis.
    Pennisi MG; Lo Giudice S; Masucci M; De Majo M; Reale S; Vitale F
    Vet Res Commun; 2008 Sep; 32 Suppl 1():S303-5. PubMed ID: 18683068
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring the reverse to normal of clinico-pathological findings and the disease free interval time using four different treatment protocols for canine leishmaniosis in an endemic area.
    Paradies P; Sasanelli M; Amato ME; Greco B; De Palo P; Lubas G
    Res Vet Sci; 2012 Oct; 93(2):843-7. PubMed ID: 22296941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of meglumine antimoniate in canine leishmaniasis.
    Lamothe J
    Vet Rec; 2004 Mar; 154(12):378. PubMed ID: 15074332
    [No Abstract]   [Full Text] [Related]  

  • 7. Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol.
    Torres M; Bardagí M; Roura X; Zanna G; Ravera I; Ferrer L
    Vet J; 2011 Jun; 188(3):346-51. PubMed ID: 20594876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol.
    Manna L; Reale S; Vitale F; Picillo E; Pavone LM; Gravino AE
    Vet J; 2008 Aug; 177(2):279-82. PubMed ID: 17553711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of leishmanial osteolytic lesions in a hypothyroid dog by partial tarsal arthrodesis.
    Franch J; Pastor J; Torrent E; Lafuente P; Diaz-Bertrana MC; Munilla A; Durall I
    Vet Rec; 2004 Oct; 155(18):559-62. PubMed ID: 15559422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraoxonase activity as a tool for clinical monitoring of dogs treated for canine leishmaniasis.
    Rossi G; Ibba F; Meazzi S; Giordano A; Paltrinieri S
    Vet J; 2014 Jan; 199(1):143-9. PubMed ID: 24188864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of serum albumin/globulin ratio after antimonial therapy in canine leishmaniasis.
    Amusategui I; Sainz A; Tesouro MA
    Ann N Y Acad Sci; 1998 Jun; 849():447-9. PubMed ID: 9668510
    [No Abstract]   [Full Text] [Related]  

  • 12. Variation of proteinuria in dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: a retrospective study.
    Pierantozzi M; Roura X; Paltrinieri S; Poggi M; Zatelli A
    J Am Anim Hosp Assoc; 2013; 49(4):231-6. PubMed ID: 23690493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of various biomarkers for kidney monitoring during canine leishmaniosis treatment.
    Pardo-Marín L; Martínez-Subiela S; Pastor J; Tvarijonaviciute A; Garcia-Martinez JD; Segarra S; Cerón JJ
    BMC Vet Res; 2017 Jan; 13(1):31. PubMed ID: 28114941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulomatous lesion on a bitch's nipple caused by Leishmania infantum.
    Gómez-Ochoa P; Gascón M; Aceña MC; Miana-Mena FJ; Castillo JA
    Vet Rec; 2005 Mar; 156(12):389. PubMed ID: 15816188
    [No Abstract]   [Full Text] [Related]  

  • 15. [Leishmaniasis: hospital and population-based incidence, and asymptomatic infection. A disease that is still with us].
    Bellido-Blasco JB; Arnedo-Pena A; Romeo-García MA; Herrero-Carot C
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):136-7. PubMed ID: 19254647
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
    Carrió J; Portús M
    BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us.
    Travi BL; Cordeiro-da-Silva A; Dantas-Torres F; Miró G
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006082. PubMed ID: 29324838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical follow-up examination after treatment of canine leishmaniasis.
    Moritz A; Steuber S; Greiner M
    Tokai J Exp Clin Med; 1998 Dec; 23(6):279-83. PubMed ID: 10622623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hair parasite load as a new biomarker for monitoring treatment response in canine leishmaniasis.
    Corpas-López V; Merino-Espinosa G; Acedo-Sánchez C; Díaz-Sáez V; Morillas-Márquez F; Martín-Sánchez J
    Vet Parasitol; 2016 Jun; 223():20-5. PubMed ID: 27198771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on therapy and prevention of canine leishmaniasis.
    Apostolopoulos N; Mitropoulou A; Thom N; Moritz A
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):315-322. PubMed ID: 30541172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.